Physician profile
Benjamin Mann
NPI 1942769716
$1,646.19
in general payments reported to CMS, 2019-2025
14 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.79 · 2023: $120 · 2024: $668 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.13 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $441.10 | 2024-2025 | |
| Philips North America LLC | $262.46 | 2022-2024 | (6571) Eagle Eye, (Bq9) Coronary Ivus |
| Pfizer INC. | $190.28 | 2023-2025 | |
| Boston Scientific Corporation | $174.96 | 2025 | Mylux Patient Kit With Mobile Device, Accolade Sr |
| E.R. Squibb & Sons, L.L.C. | $166.74 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Abiomed | $62.37 | 2025 | |
| Novo Nordisk INC | $54.79 | 2025 | Wegovy |
| Medtronic, INC. | $44.29 | 2024 | Micra, Mycarelink |
| Teleflex LLC | $34.80 | 2025 | Arrow |
| Lexicon Pharmaceuticals, INC. | $27.35 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.55 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $22.39 | 2025 | |
| Biotronik INC. | $16.11 | 2025 | Biomonitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.